According to Raphael Rostenne, CTO of EyeCarePro, "anything that takes time" has the potential to frustrate patients, ...
Kansas, Tennessee, and Vermont expanded optometric scope in 2026, while vision plan reform and a proposed Medicare fee ...
The FDA approved Lucamzi (ranibizumab-blrz; Xbrane Biopharma), a biosimilar to Lucentis (ranibizumab; Genentech), for neovascular (wet) age-related macular degeneration (AMD) and ...
The meeting, which comes a year after the agency issued a complete response letter in October 2025,2 was held from 8:30 am-3 ...
What to take away on PBM, hormonal eye health, and GLP-1 receptor agonists from this year’s meeting.
This week’s top stories include pipeline updates in dry eye, retinitis pigmentosa, contact lens hygiene, and more.
Amanda Nanasy, OD, discussed how sports can open the door to eye care for underserved athletes and what goes into her ...
Raphael Rostenne discusses what a good phone call looks like and contributes to successful patient interactions with host Diana Canto-Sims, OD. This episode of The Independent Advantage features ...
FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites. The FDA granted orphan drug designation to OCT-980, an investigational oral small molecule ...
The licaminlimab trial enrolled 176 patients, two-thirds with a TNFR1 variant tied to stronger response. Data expected late 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results